Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN)

CAPS Rating: 3 out of 5

A biopharmaceutical company committed to improving the lives of people with diabetes, obesity and other diseases through the discovery, development and commercialization of innovative medicines.

Recs

0
Player Avatar finmasterflex (< 20) Submitted: 1/14/2011 4:19:01 PM : Outperform Start Price: $14.51 AMLN Score: +75.15

betting on drug approval soon

Featured Broker Partners


Advertisement